EGFR and exanthem: Skin rash of grade 2 and greater (NCI-CTC) is dose dependent and occurs in 20–50% of patients treated with EGFR-directed therapies such as gefitinib (Fukuoka et al, 2003), erlotinib (Soulieres et al, 2004) and cetuximab (Saltz et al, 2004).